PARP inhibition in breast cancer: progress made and future hopes

PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (gBRCAm) carriers. The recent OlympiA trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gBRCAm carriers with HER2-negative high-risk earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tung, Nadine, Garber, Judy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993852/
https://www.ncbi.nlm.nih.gov/pubmed/35396508
http://dx.doi.org/10.1038/s41523-022-00411-3
_version_ 1784683990554247168
author Tung, Nadine
Garber, Judy E.
author_facet Tung, Nadine
Garber, Judy E.
author_sort Tung, Nadine
collection PubMed
description PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (gBRCAm) carriers. The recent OlympiA trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gBRCAm carriers with HER2-negative high-risk early-stage breast cancer. The current article addresses some for the questions raised by OlympiA regarding how to incorporate PARP inhibitors into the treatment of early-stage breast cancer as well as future directions for PARP inhibitors in breast cancer treatment and prevention.
format Online
Article
Text
id pubmed-8993852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89938522022-04-27 PARP inhibition in breast cancer: progress made and future hopes Tung, Nadine Garber, Judy E. NPJ Breast Cancer Comment PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (gBRCAm) carriers. The recent OlympiA trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gBRCAm carriers with HER2-negative high-risk early-stage breast cancer. The current article addresses some for the questions raised by OlympiA regarding how to incorporate PARP inhibitors into the treatment of early-stage breast cancer as well as future directions for PARP inhibitors in breast cancer treatment and prevention. Nature Publishing Group UK 2022-04-08 /pmc/articles/PMC8993852/ /pubmed/35396508 http://dx.doi.org/10.1038/s41523-022-00411-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Tung, Nadine
Garber, Judy E.
PARP inhibition in breast cancer: progress made and future hopes
title PARP inhibition in breast cancer: progress made and future hopes
title_full PARP inhibition in breast cancer: progress made and future hopes
title_fullStr PARP inhibition in breast cancer: progress made and future hopes
title_full_unstemmed PARP inhibition in breast cancer: progress made and future hopes
title_short PARP inhibition in breast cancer: progress made and future hopes
title_sort parp inhibition in breast cancer: progress made and future hopes
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993852/
https://www.ncbi.nlm.nih.gov/pubmed/35396508
http://dx.doi.org/10.1038/s41523-022-00411-3
work_keys_str_mv AT tungnadine parpinhibitioninbreastcancerprogressmadeandfuturehopes
AT garberjudye parpinhibitioninbreastcancerprogressmadeandfuturehopes

Ejemplares similares